| |
|
|
|
|
| |
 |
Novozymes Biopharma secures albucult supply agreement for medical devices |
 |
|
This agreement will result in the launch of the first Class III medical device containing albucult |
|
|
|
|
|
| |
 |
TxCell successfully completes preclinical development of TX-RAD in arthriti |
 |
|
Favorable results mean that TxCell will start a new Phase I/IIa clinical trial |
|
|
|
|
|
| |
 |
Spanish biotech companies in the top three position in successful projects |
 |
|
Tailoring the European Framework Programmes and financing for biotech SMEs: Improvements and Challenges. |
|
|
|
|
|
| |
 |
LSP Announces Acquisition of Portfolio Company FlowCardia, Inc. |
 |
|
Bard is worldwide leader in products that focus on disease state management in three key areas: vascular, urology and oncology |
|
|
|
|
|
| |
 |
Hybrigenics determines the maximum dosage of inecalcitol |
 |
|
Excellent clinical tolerance at high circulating levels broadens therapeutic scope beyond prostate cancer |
|
|
|
|
|
| |
 |
Aragen Bioscience, Inc. and CEVEC Sign License Agreement |
 |
|
License Agreement for Human CAP® and CAP-TTM Technology |
|
|
|
|
|
| |
 |
BioFocus and CHDI Foundation, Inc. enter new five-year collaboration |
 |
|
Collaboration for Huntington’s disease therapeutics. Expands and extends collaboration initiated in 2005. Largest external collaboration to date for BioFocus. |
|
|
|
|
|
| |
 |
PharmaMar presents new trials with three marine-based drugs |
 |
|
The trials provide new information on the drugs' action mechanisms and antitumour potential |
|
|
|
|
|
| |
 |
Biocitech technology park posts record number of partnerships in 2009 |
 |
|
Paris life science park residents strike 37 deals with outside companies and continue to increase rate of scientific achievement |
|
|
|
|
|
| |
 |
C21 BioVentures™ 2010 update |
 |
|
Where Early Stage Innovators and Investors Get Deals Done |
|
|
|
|
|
| |
 |
C21 BioVentures™ 2010 |
 |
|
Lunch Keynote Presentation by Frederick Frank |
|
|
|
|
|
| |
 |
Novozymes Biopharma announces new study data using Recombumin® |
 |
|
Recombumin® used in protein drug formulation |
|
|
|
|
1 2 Siguiente > |
|